The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate

Parasitology Research

Volumn 110, Issue 3, 2012, Pages 1113-1117

  Shokri, Azar ^a   Sharifi, Iraj ^b   Khamesipour, Ali ^c   Nakhaee, Nozar ^d   Harandi, Majid Fasihi ^b   Nosratabadi, Jafar ^b   Parizi, Maryam Hakimi ^b   Barati, Mohammad ^b  

^a HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; VERAPAMIL; ANTIPROTOZOAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

AMASTIGOTE; ANIMAL CELL; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GROWTH INHIBITION; IC 50; IN VITRO STUDY; LEISHMANIA TROPICA; MACROPHAGE; MOUSE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROMASTIGOTE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PARASITOLOGY; PERITONEUM MACROPHAGE; SKIN LEISHMANIASIS;

ANIMALIA; LEISHMANIA TROPICA;

ANIMALS; ANTIPROTOZOAL AGENTS; CALCIUM CHANNEL BLOCKERS; COLORIMETRY; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; INHIBITORY CONCENTRATION 50; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; VERAPAMIL;

EID: 84861206055     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-011-2599-6     Document Type: Article

References (21)

1. Alvar J, Croft S, Olliaro P (2006) Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61:223-274 (Pubitemid 43777022)
2. Bellamy WT (1996) P-glycoprotein and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161-183
3. Carrio MC, Reiva C, Gallego M, Arboix M, Portus M (2000) Leishmania infantum: stage specific activity of pentavalent antimony related with the assay conditions. Exp Parasitol 95: 209-214
4. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19(1):11-26
5. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305-318 (Pubitemid 38842803)
6. Firooz A, Khamesipour A, GhoorchiMH, Nassiri-Kashani M, Eskandari SE,Khatami A,Hooshmand B,Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y (2006) Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch Dermatol 142 (12):71575-71579
7. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M (2006) Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3(5):659-667 (Pubitemid 43807035)
8. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, Mohebali M (2007) Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 101 (5):1319-1322 (Pubitemid 47389435)
9. Jha TK (2006) Drug unresponsiveness and combination therapy for kala-Azar. Indian J Med Res 123(3):389-398 (Pubitemid 43905577)
10. Khatami A, Firooz A, Gorouhi F, Dowlati Y (2007) Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57(2): 335.e1-29
11. Layegh P, Pezeshkipoor F, Soruri AH, Navaifar P, Moghyman T (2009) Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 80(2):172-175
12. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sakhs D (1999) Evidence that the high incidence of treatment failure in Indian Kala azar is due the emergence of antimony resistant strains of Leishmania donovani. J Infect Dis 180(2):564-567 (Pubitemid 30256350)
13. Martin SK, Oduola AM, Milhous WK (1987) Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901 (Pubitemid 17019130)
14. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL (2007) Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris 13-15June, 2006. Kinetoplastid Biol Dis 24(6):3.
15. Moreno D, Plano D, Baquedano Y, Jiménez-Ruiz A, Palop JA, Sanmartin C (2011) Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates. Parasitol Res 108(1):233-239
16. Pour R, Sharifi I, Kazemi B, Zarean M (2011) Identification of nonresponsive isolates to glucantime in patients with cutaneous leishmaniasis in Bam. J Kerman Univ Med Sci 18(2):123-133
17. Prasad V, Kaur J, Dey CS (2000) Arsenite-resistant Leishmania donovani promastigotes express an enhanced membrane P-type adenosine triphosphatase activity that is sensitive to verapamil treatment. Parasitol Res 86(8):661-664
18. Ranjini Valiathan ML, Dubey RC et al (2006) Leishmania donovani: Effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 114:103-108
19. Shakya N, Sane SA, Gupta S (2011) Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator-picroliv. Parasitol Res 108(4):793-800
20. Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, Nadim A, Modabber F (2010) Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Int J Dermatol 49:557-561
21. Tafaghodi M, Khamesipour A, Jaafari MR (2011) Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res 108(5):1265-1273